Regeneron Pharmaceuticals, Inc.
REGN
$907.32
$7.160.80%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 3.22B | 3.22B | 3.09B | 3.05B | 3.29B |
| Total Other Revenue | 212.50M | 138.30M | 69.30M | 116.00M | 127.70M |
| Total Revenue | 3.43B | 3.36B | 3.16B | 3.16B | 3.41B |
| Cost of Revenue | 1.69B | 1.51B | 1.49B | 1.56B | 1.58B |
| Gross Profit | 1.74B | 1.85B | 1.67B | 1.60B | 1.83B |
| SG&A Expenses | 737.70M | 640.50M | 652.00M | 601.10M | 660.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -500.00K | -500.00K | -600.00K | -500.00K | -6.60M |
| Total Operating Expenses | 2.43B | 2.15B | 2.14B | 2.16B | 2.24B |
| Operating Income | 1.00B | 1.21B | 1.02B | 1.00B | 1.18B |
| Income Before Tax | 1.15B | 1.11B | 1.08B | 858.00M | 1.32B |
| Income Tax Expenses | -12.00M | 103.00M | 114.50M | 40.20M | 127.60M |
| Earnings from Continuing Operations | 1.16B | 1.01B | 968.40M | 817.80M | 1.20B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.16B | 1.01B | 968.40M | 817.80M | 1.20B |
| EBIT | 1.00B | 1.21B | 1.02B | 1.00B | 1.18B |
| EBITDA | 1.12B | 1.32B | 1.12B | 1.10B | 1.28B |
| EPS Basic | 10.88 | 9.48 | 9.05 | 7.64 | 11.19 |
| Normalized Basic EPS | 6.56 | 7.88 | 6.51 | 6.30 | 7.44 |
| EPS Diluted | 10.19 | 8.89 | 8.50 | 7.17 | 10.49 |
| Normalized Diluted EPS | 6.15 | 7.39 | 6.11 | 5.91 | 6.98 |
| Average Basic Shares Outstanding | 106.60M | 106.30M | 107.00M | 107.10M | 107.00M |
| Average Diluted Shares Outstanding | 113.80M | 113.40M | 113.90M | 114.00M | 114.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
